A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä
Long-term Survival of Stage IV Melanoma Patients Treated with BOLD Combination Chemotherapy and Intermediate-dose Subcutaneous Interferon-alpha
Tekijät: Kalle Mattila, Pirita Raanta, Valtteri Lahtela, Seppo Pyrhonen, Ilkka Koskivuo, Pia Vihinen
Kustantaja: INT INST ANTICANCER RESEARCH
Julkaisuvuosi: 2018
Journal: Anticancer Research
Tietokannassa oleva lehden nimi: ANTICANCER RESEARCH
Lehden akronyymi: ANTICANCER RES
Vuosikerta: 38
Numero: 11
Aloitussivu: 6393
Lopetussivu: 6397
Sivujen määrä: 5
ISSN: 0250-7005
DOI: https://doi.org/10.21873/anticanres.12999
Tiivistelmä
Background: Immune checkpoint and serine/threonine-protein kinase inhibitors have become a standard of care for advanced cutaneous melanoma, but dacarbazine-based chemotherapies are occasionally used. This study assessed the long-term efficacy of chemoimmunotherapy (bleomycin, vincristine, lomustine and dacarbazine with/ without subcutaneous interferon-alpha: BOLD-INF-alpha) as real-world data in patients with metastatic melanoma not eligible for clinical trials. Patients and Methods: Medical data of 146 patients with stage IV melanoma who had received BOLD/BOLD-INF alpha regimen during 1991-2010 were analyzed. Results: The median overall survival was 8.9 months (95% confidence interval=7.5-10.4 months). The 1-year survival rate was 36%, 2-year 18%, and 5-year 13%. The 5-year survival rates in the M1a, M1b and M1c subgroups were 28%, 10% and 6%, respectively. Overall, 7% (n=11) of the patients were alive at the end of the follow-up. Conclusion: Our study showed similar overall survival among patients with stage IV cutaneous melanoma treated with BOLD/BOLD-INF alpha as noted previously with chemotherapy.
Background: Immune checkpoint and serine/threonine-protein kinase inhibitors have become a standard of care for advanced cutaneous melanoma, but dacarbazine-based chemotherapies are occasionally used. This study assessed the long-term efficacy of chemoimmunotherapy (bleomycin, vincristine, lomustine and dacarbazine with/ without subcutaneous interferon-alpha: BOLD-INF-alpha) as real-world data in patients with metastatic melanoma not eligible for clinical trials. Patients and Methods: Medical data of 146 patients with stage IV melanoma who had received BOLD/BOLD-INF alpha regimen during 1991-2010 were analyzed. Results: The median overall survival was 8.9 months (95% confidence interval=7.5-10.4 months). The 1-year survival rate was 36%, 2-year 18%, and 5-year 13%. The 5-year survival rates in the M1a, M1b and M1c subgroups were 28%, 10% and 6%, respectively. Overall, 7% (n=11) of the patients were alive at the end of the follow-up. Conclusion: Our study showed similar overall survival among patients with stage IV cutaneous melanoma treated with BOLD/BOLD-INF alpha as noted previously with chemotherapy.
Turun yliopiston Tutkimustietojärjestelmän portaali